Adrenocortical Neoplasia

Adrenocortical Neoplasia refers to a spectrum of abnormal growths originating from the adrenal cortex, the outer layer of the adrenal glands responsible for producing steroid hormones including glucocorticoids, mineralocorticoids, and androgens. These neoplasms encompass both benign and malignant tumors that can affect hormone secretion and systemic physiology.

Classification

Benign Adrenocortical Tumors

Benign tumors primarily include adrenocortical adenomas, which are usually small, well-circumscribed masses. They may be hormonally active or inactive. Functional adenomas often cause clinical syndromes due to excess hormone production, such as Cushing’s syndrome (glucocorticoid excess), primary aldosteronism (aldosterone excess), or virilization (androgen excess).

Malignant Adrenocortical Carcinomas

Adrenocortical carcinomas (ACC) are rare but aggressive tumors with a poor prognosis. They tend to be large, invasive, and frequently secrete excess hormones leading to clinical syndromes similar to adenomas but with more severe systemic effects. ACC may metastasize to distant organs, such as the liver and lungs.

Pathophysiology

Adrenocortical neoplasia arises from genetic and molecular alterations that disrupt normal cell growth and hormone production. Common molecular abnormalities include mutations in tumor suppressor genes (e.g., TP53), activation of oncogenes (e.g., IGF2 overexpression), and dysregulation of signaling pathways such as Wnt/β-catenin. These changes lead to unregulated proliferation, hormone hypersecretion, and evasion of apoptosis.

Hormonal overproduction by neoplastic adrenal cells causes paraneoplastic syndromes. For example:

• Cortisol excess causes Cushing’s syndrome, characterized by central obesity, hypertension, glucose intolerance, and muscle weakness.
• Aldosterone excess leads to hypertension and hypokalemia.
• Androgen or estrogen excess can cause virilization or feminization, respectively.

Clinical Presentation

Symptoms

Clinical manifestations depend on tumor size, invasiveness, and hormone secretion:

• Hormone-producing tumors present with endocrine syndromes such as Cushing’s syndrome, Conn’s syndrome, or virilization.
• Nonfunctional tumors may be asymptomatic and discovered incidentally on imaging.
• Large or invasive tumors can cause abdominal pain, palpable mass, or symptoms from local invasion.

Physical Examination

Findings may include hypertension, moon facies, abdominal obesity, skin changes (striae, bruising), muscle wasting, or signs of androgen excess such as hirsutism or gynecomastia.

Diagnosis

Imaging

• CT scan is the primary modality, revealing tumor size, shape, density, and local invasion.
• MRI may be used for characterization and differentiation from other adrenal masses.
• PET scan can assess metabolic activity and detect metastases.

Laboratory Evaluation

• Hormonal assays to identify cortisol, aldosterone, androgen, and estrogen levels.
• Dexamethasone suppression test for cortisol-producing tumors.
• Plasma renin and aldosterone measurements for primary aldosteronism.

Histopathology

Definitive diagnosis requires tissue sampling, often through surgical excision. Histologic features differentiate adenomas from carcinomas, with criteria including mitotic rate, necrosis, capsular invasion, and nuclear atypia. The Weiss system is commonly used for assessing malignancy likelihood.

Treatment

Surgical Management

Complete surgical resection is the primary treatment for localized tumors, especially carcinomas. Adrenalectomy can be performed laparoscopically or via open surgery depending on tumor size and invasion.

Medical Therapy

• Hormone-secreting tumors may require medical management of hormone excess symptoms pre- and post-operatively.
• Mitotane is an adrenolytic agent used in ACC to reduce tumor burden and control hormone secretion.
• Chemotherapy and radiation therapy have limited but adjunctive roles in advanced or metastatic disease.

Follow-up

Long-term monitoring includes imaging and hormonal evaluation to detect recurrence or metastasis.

Prognosis

The prognosis varies widely based on tumor type and stage at diagnosis:

• Adenomas generally have an excellent prognosis after surgical removal.
• Adrenocortical carcinoma carries a poor prognosis with five-year survival rates below 40% for advanced disease.
• Early detection and complete resection improve outcomes significantly.

Epidemiology and Risk Factors

Adrenocortical neoplasms are rare, with carcinomas representing less than 0.2% of all cancers. Incidence peaks in early childhood and in the fourth to fifth decades of life. Risk factors include genetic syndromes such as Li-Fraumeni syndrome, Beckwith-Wiedemann syndrome, and multiple endocrine neoplasia type 1 (MEN1).

Molecular and Genetic Insights

Molecular profiling has identified key pathways involved in adrenocortical tumorigenesis:

• TP53 mutations are frequent in ACC, especially in pediatric populations.
• Overexpression of insulin-like growth factor 2 (IGF2) promotes cellular proliferation.
• Alterations in Wnt/β-catenin signaling contribute to tumor growth.
• Epigenetic modifications and microRNA dysregulation are emerging areas of research.

These insights offer potential targets for novel therapeutic interventions.

Summary Table of Adrenocortical Neoplasia Characteristics

This comprehensive overview defines and details the clinical, pathological, and molecular aspects of adrenocortical neoplasia, encompassing the spectrum from benign adenomas to aggressive carcinomas with significant clinical implications.